1. Home
  2. SPCB vs OTLK Comparison

SPCB vs OTLK Comparison

Compare SPCB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SuperCom Ltd. (Israel)

SPCB

SuperCom Ltd. (Israel)

HOLD

Current Price

$10.59

Market Cap

45.3M

Sector

Technology

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.44

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPCB
OTLK
Founded
1988
2010
Country
Israel
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.3M
38.7M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SPCB
OTLK
Price
$10.59
$0.44
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$3.83
AVG Volume (30 Days)
120.5K
12.5M
Earning Date
11-13-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.84
N/A
Revenue
$26,739,000.00
$1,413,535.00
Revenue This Year
N/A
$1,578.49
Revenue Next Year
$27.13
$153.58
P/E Ratio
$11.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.06
$0.45
52 Week High
$14.00
$3.39

Technical Indicators

Market Signals
Indicator
SPCB
OTLK
Relative Strength Index (RSI) 63.72 23.19
Support Level $8.16 $0.51
Resistance Level $9.15 $0.54
Average True Range (ATR) 0.66 0.04
MACD 0.23 0.03
Stochastic Oscillator 79.87 13.24

Price Performance

Historical Comparison
SPCB
OTLK

About SPCB SuperCom Ltd. (Israel)

SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: